Riskpilot← Back to searchSign inGet full accessFredAx AB
ABActiveOrg 5568750656Scheelevägen 2Manufacture of basic pharmaceutical products · NACE 2110Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
-57% vs 2023
Equity ratio
68.6%
Financial strength
Net profit 2024
SEK 177K
+485% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -74K | -57% |
| Net profit | SEK 177K | +485% |
| Total assets | SEK 10,8M | +3% |
| Equity | SEK 7,4M | +2% |
| Employees | 0 | — |
Legal name
FredAx AB
Org number
5568750656
Legal form
Aktiebolag
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
7 december 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva utveckling av läkemedel och därmed förenlig verksamhet.
Address
Scheelevägen 2
Email
johan.drott@diaprost.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 200 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −686 | −987 | −2 | −47 | −74 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −686 | −987 | −2 | −47 | −74 |
| Net financials | −4 | — | — | 1 | 282 |
| Profit before tax | −5 | −7 | −2 | −46 | 209 |
| Tax | −0 | −0 | −0 | −0 | −32 |
| Net profit | −5 | −7 | −2 | −46 | 177 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 292 | 7 269 | 10 205 | 10 463 | 10 767 |
| Equity | 7 265 | 7 258 | 7 257 | 7 211 | 7 387 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 27 | 11 | 2 949 | 3 252 | 3 380 |
| Total debt | 27 | 11 | 2 949 | 3 252 | 3 380 |
EBITDA margin
-7400000.0%
This company
15.8%
Market median
-46835543% vs market
20202024
Equity ratio
68.6%
This company
38.2%
Market median
+80% vs market
20202024
Return on equity
2.4%
This company
18.4%
Market median
-87% vs market
20202024
Net profit margin
17700000.0%
This company
8.1%
Market median
+218518419% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2022 | |
LJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Diaprost AB
FredAx AB Board members of FredAx AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Henrik Alexander Brodström | Audit | 0 companies |
| Lars Johan Lennart Drott | Chief Executive Officer | 0 companies |
| Sven Niklas Anders Axelsson | Deputy Board Member | 0 companies |
| Hans Åke Lennart Fredriksson | Deputy Board Member | 0 companies |